GMAB Stock Recent News

Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 4 3 rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 1 4 , 202 5 , 12 :00 AM CET on January 15, 2025 . The live and archived webcast of the presentation will be available on Genmab's website at https://ir.genmab.com/events-presentations.

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), d.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following.

Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results f.

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish biotech exclusive global rights to develop and commercialise a monoclonal antibody from the UK drug developer's GlyMab platform.

Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

Company Announcement COPENHAGEN, Denmark; December 3, 2024 –  Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

Media Release COPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will take part in a fireside chat at Citi's 2024 Global Healthcare Conference on December 3 , 202 4 at 8 :30 PM CET / 2 : 30 P M EST. A webcast of the event will be available on Genmab's website at https://ir.genmab.com/events-presentations.